Chromocell Therapeutics(CHRO) - 2025 Q4 - Annual Results

Exhibit 99.1 Pelthos Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results ZELSUVMI™ net product revenue grew 28% Quarter over Quarter to $9.1 million, bringing total ZELSUVMI net product revenue to $16.2 million, for the period from the launch in July 2025 through December 31, 2025. Total revenue including licensing revenue was $16.8 million for 2025. 8,948 ZELSUVMI units prescribed by 2,712 unique prescribers for fiscal year 2025, with a 129% quarter over quarter increase in units dis ...